Trending/Dr. Vicente Torres
- November 4, 2017
Vicente Torres, M.D., Ph.D., discusses new findings on tolvaptan as autosomal dominant polycystic kidney disease treatment
ROCHESTER, Minn. – A phase 3 trial studying the effects of tolvaptan has found that the drug slowed the rate of decline in kidney function…
No information found.